

RESPONSE UNDER 37 CFR 1.116
EXPERIMENTAL PROCEDURE
EXAMINING GROUP 1645

PATENT

Rev 05/03


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Kerstin Krieglstein
Application No. : 09/786,435
Filed : March 20, 2001
Confirmation No. : 1324
For : USE OF TGF-BETA INHIBITORS FOR TREATING
CEREBRAL DISORDERS
Examiner : Vanessa L. Ford
Attorney's Docket : MBP-005XX

TC Art Unit: 1645

I hereby certify that this correspondence is being sent via facsimile to
Examiner Vanessa L. Ford, Group Art Unit 1645, Fax No. (703) 308-4242,
on 10-17-03.

By:


Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant(s)

AMENDMENT UNDER 37 C.F.R. §1.116

RECEIVED
CENTRAL FAX CENTER

OCT 20 2003

Via Facsimile
Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL

Sir:

In response to the final Office Action dated June 17, 2003
(Paper No. 10), please amend the above-identified patent
application as follows.

WEINGARTEN, SCHURGIN,
GAGNEBIN & DEBOVICI LLP
TEL. (617) 542-2290
FAX. (617) 431-0313